Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$128.45
-0.5%
$129.57
$99.71
$141.23
$223.48B0.746.12 million shs5.27 million shs
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
C$0.00
C$11.77
C$26.00
C$2.15BN/A229,895 shs4.61 million shs
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
$4.57
-2.1%
$5.64
$3.96
$9.85
$1.66B0.342.62 million shs1.29 million shs
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$15.19
$8.13
$31.32
$24.33M0.4123,945 shs237,144 shs
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
-2.19%-3.18%+1.72%-1.12%+23.15%
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
-2.40%-1.89%+7.98%-26.57%-34.46%
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.00%0.00%+8.57%+1.33%-40.91%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.9763 of 5 stars
3.44.04.24.53.02.52.5
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
4.0899 of 5 stars
2.92.00.04.02.71.71.9
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
3.4533 of 5 stars
3.05.00.04.20.60.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.84
Moderate Buy$142.5911.01% Upside
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
0.00
N/AN/AN/A
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
1.86
Reduce$7.4262.29% Upside
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
2.00
Hold$83.52∞ Upside

Current Analyst Ratings Breakdown

Latest ABT, AUP, BHC, and CARA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2025
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$8.50 ➝ $10.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$133.00 ➝ $145.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$132.00 ➝ $142.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$140.00 ➝ $145.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$117.00 ➝ $127.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$136.00 ➝ $147.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$158.00 ➝ $159.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$135.00 ➝ $145.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$135.00 ➝ $137.00
4/7/2025
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform$9.00 ➝ $8.50
3/10/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$133.00 ➝ $150.00
(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$42.34B5.28$5.53 per share23.22$22.36 per share5.74
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
C$57.59M0.00N/A6.75C$2.59 per share0.00
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
$9.73B0.17$4.86 per share0.94($0.89) per share-5.13
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$7.14M0.00N/AN/A$12.58 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.7116.7922.422.5231.95%20.74%11.19%7/17/2025 (Estimated)
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
N/A-C$1.48N/AN/AN/AN/AN/AN/AN/A
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
-$46M-$0.11N/A0.980.37-0.48%-577.82%5.24%7/30/2025 (Estimated)
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/A

Latest ABT, AUP, BHC, and CARA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/16/2025Q1 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.07$1.09+$0.02$0.76$10.38 billion$10.36 billion
2/19/2025Q4 2024
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
$1.65$1.21-$0.44$0.25$2.51 billion$2.56 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.84%+7.17%30.61%54 Years
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
N/AN/AN/AN/AN/A
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/AN/AN/AN/AN/A

Latest ABT, AUP, BHC, and CARA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/21/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.75%4/15/20254/15/20255/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.32
1.60
1.14
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
2.69
11.93
11.02
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
N/A
0.86
0.62
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/A
4.77
4.71

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
N/A
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
78.65%
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
44.66%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
115,0001.74 billion1.73 billionOptionable
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
300128.40 millionN/ANot Optionable
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
19,900362.40 million338.06 millionOptionable
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
804.57 million4.43 millionOptionable

Recent News About These Companies

Tvardi maps out path to Phase II data after Cara merger
Cara Therapeutics board approves 1-for-3 reverse stock split
Cara Therapeutics trading halted, news pending

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$128.45 -0.60 (-0.46%)
As of 03:48 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals TSE:AUP

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Bausch Health Companies stock logo

Bausch Health Companies NYSE:BHC

$4.57 -0.10 (-2.14%)
As of 03:48 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Cara Therapeutics stock logo

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.